CLAIMS

1. Use of a combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof and an interferon (IFN) agent or a functional fragment thereof, for preparing a medicament for use for treating a HBV infection,

wherein the TNFRSF agonist or a functional fragment thereof is TWEAK, or a functional fragment thereof.

2. Use of a bifunctional immunostimulatory fusion protein for preparing a medicament for use for treating a HBV infection, the bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof, an interferon (IFN) agent or a functional fragment thereof, and a linker,

wherein the TNFRSF agonist or a functional fragment thereof is TWEAK, or a functional fragment thereof.

3. The use according to claim 1 or 2, wherein the IFN agent or a functional fragment thereof is selected from the group consisting of a Type I IFN agent, a Type II IFN agent and a Type III IFN agent, or functional fragments thereof.

4. The use according to any one of claims 1 to 3, wherein the IFN agent or a functional fragment thereof is IFNα, IFNβ, IFNγ or IFNλ, or functional fragments thereof.

5. The use according to any one of claims 1 to 4, wherein the IFN agent or a functional fragment thereof is IFNβ or IFNγ, or functional fragments thereof.

6. The use according to any one of claims 1 to 5, wherein the IFN agent or a functional fragment thereof is IFNβ, or a functional fragment thereof.

7. The use according to any one of claims 1 to 4, wherein the IFN agent or a functional fragment thereof is IFNα, or a functional fragment thereof.

8. The use according to any one of claims 1 or 3 to 7, wherein the TNFRSF agonist or a functional fragment thereof and the IFN agent or a functional fragment thereof are comprised in a single pharmaceutical composition.

9. The use according to any one of claims 1 or 3 to 7, wherein the TNFRSF agonist or a functional fragment thereof and the IFN agent or a functional fragment thereof are comprised in distinct pharmaceutical compositions.

10. The use according to any one of claims 2 to 7, wherein the linker is a peptide linker incorporating a multimerization domain.

11. The use according to claim 10, wherein the multimerization domain is selected among a tenascin trimerization motif, a collectin trimerization domain, streptavidin, an IgE heavy-chain domain 2 (EHD2), an IgM heavy-chain domain 2 (MHD2), an IgG heavy-chain domain 3 (GHD3), an IgA heavy-chain domain 3 (AHD2), an IgD heavy-chain domain 3 (DHD3), an IgE heavy-chain domain 4 (EHD4), an IgM heavy-chain domain 4 (MHD4), an Fc domain, an uteroglobin dimerization domain and a leucine zipper (LZ) domain.

12. A pharmaceutical composition comprising:

a TNFRSF agonist or a functional fragment thereof; and

an interferon (IFN) agent or a functional fragment thereof

wherein the TNFRSF agonist or a functional fragment thereof is TWEAK, or a functional fragment thereof.

13. A pharmaceutical composition comprising a bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof, an interferon (IFN) agent or a functional fragment thereof, and a linker,

wherein the TNFRSF agonist or a functional fragment thereof is TWEAK, or a functional fragment thereof.

14. A combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof and an interferon (IFN) agent or a functional fragment thereof, for use for treating a HBV infection,

wherein the TNFRSF agonist or a functional fragment thereof is TWEAK, or a functional fragment thereof.

15. A bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof, an interferon (IFN) agent or a functional fragment thereof, and a linker, for use for treating a HBV infection,

wherein the TNFRSF agonist or a functional fragment thereof is TWEAK, or a functional fragment thereof.

16. The pharmaceutical composition according to claims 12 or 13, the combination according to claim 14 or the bifunctional immunostimulatory fusion protein according to claim 15, wherein the IFN agent is according to any one of claims 3 to 7.